Dianthus CAO granted 55,000 stock options

Dianthus Therapeutics reported a new equity award to its chief accounting officer, Edward Carr.

Accepted by SEC EDGAR 02/04/2026 - 05:42 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Dianthus Therapeutics reported a new equity award to its chief accounting officer, Edward Carr. On February 3, 2026, he received a stock option for 55,000 shares of common stock with an exercise price of $52.46 per share, expiring on February 3, 2036.

The option vests in equal monthly installments over four years after January 1, 2026, as long as he continues to serve the company on each vesting date. This filing reflects routine equity-based compensation rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 55,000 shares

Grant/Award 1 txn

Insider CARR EDWARD

Role CHIEF ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 55,000 contracts (Direct)

Footnotes (1)

1. F1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dianthus Therapeutics (DNTH) report in this Form 4 filing?

Dianthus Therapeutics reported a stock option grant to its chief accounting officer, Edward Carr. He received options for 55,000 shares of common stock, documenting an equity compensation award rather than a market trade in existing shares.

How many Dianthus Therapeutics (DNTH) options were granted to Edward Carr?

Edward Carr was granted stock options covering 55,000 shares of Dianthus Therapeutics common stock. These options give him the right to buy those shares in the future at a fixed exercise price stated in the award, subject to the vesting schedule.

What is the exercise price of Edward Carr’s Dianthus (DNTH) stock options?

The exercise price of Edward Carr’s Dianthus stock options is $52.46 per share. This price is the fixed amount he would pay per share to exercise the options, regardless of the market price at the time of exercise, assuming they have vested.

When do Edward Carr’s Dianthus (DNTH) stock options vest?

The options vest in equal monthly installments over four years after January 1, 2026. Each month, a portion becomes exercisable, provided Edward Carr continues serving Dianthus on each vesting date, aligning his compensation with ongoing employment.

When do the Dianthus (DNTH) stock options granted to Edward Carr expire?

The stock options granted to Edward Carr expire on February 3, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Dianthus common shares, regardless of whether they had previously vested.

Is this Dianthus (DNTH) Form 4 a purchase or sale of existing shares?

This Form 4 reflects a grant of stock options, not a purchase or sale of existing common shares. It records an equity compensation award giving Edward Carr the right to buy stock in the future under specified terms and vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARR EDWARD

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$52.46	02/03/2026		A		55,000		(1)	02/03/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Edward Carr	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.